{"id":63284,"date":"2021-09-29T13:03:48","date_gmt":"2021-09-29T11:03:48","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&#038;p=63284"},"modified":"2026-05-08T12:35:28","modified_gmt":"2026-05-08T10:35:28","slug":"leo-pharma-and-veeva-systems-partner-for-patient-centric-digital-trials","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/leo-pharma-and-veeva-systems-partner-for-patient-centric-digital-trials\/","title":{"rendered":"LEO Pharma and ³Ô¹Ï±¬ÁÏ Systems Partner for Patient-centric Digital Trials"},"content":{"rendered":"<p align=\"center\"><em>Connected solution aims to deliver faster trials and a better patient experience<\/em><\/p>\n<p><strong>BALLERUP, DENMARK and BARCELONA, SPAIN \u2014 29 Sept. 2021 \u2014<\/strong> <a href=\"https:\/\/www.leo-pharma.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">LEO Pharma<\/a>, a global leader in medical dermatology, and <a href=\"\/eu\/\">³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced a strategic technology partnership to enable scalable digital trials that are patient-centric and paperless. <\/p>\n<p>Building on its success with the ³Ô¹Ï±¬ÁÏ Clinical Operations Suite, LEO Pharma will complete its standardization on existing ³Ô¹Ï±¬ÁÏ clinical technology, be an early adopter of future ³Ô¹Ï±¬ÁÏ solutions, and help to shape the ³Ô¹Ï±¬ÁÏ digital trials roadmap. By adopting technology and optimized business processes, LEO Pharma plans to achieve the following while maintaining the highest standards of data accuracy, regulatory compliance, and patient safety:<\/p>\n<ul>\n<li>Significantly improved patient experience<\/li>\n<li>Increased patient diversity through decentralized trials<\/li>\n<li>Higher accuracy in clinical data<\/li>\n<li>25% reduction in clinical trial cost<\/li>\n<li>25% reduction in clinical trial time<\/li>\n<\/ul>\n<p>LEO Pharma will utilize the integrated suite of ³Ô¹Ï±¬ÁÏ clinical products, including eTMF, CTMS, CDMS, Site Connect, eConsent, ePRO, Virtual Visits, and eSource.  <\/p>\n<p>\u201cWe\u2019ve been exploring ways to transform clinical trials, but COVID-19 sped up this process. By promptly responding to changing market dynamics, we kept our trials going without delay. Partnering with ³Ô¹Ï±¬ÁÏ supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business,\u201d said J\u00f6rg M\u00f6ller, executive vice president and head of R&#038;D at LEO Pharma. \u201c³Ô¹Ï±¬ÁÏ\u2019s track record of product excellence makes it the ideal long-term partner to help us achieve this, enabling us to help patients faster and better.\u201d <\/p>\n<p>\u201cWe\u2019re thrilled and honored to extend our longstanding partnership with LEO Pharma to be an early adopter of our full digital trials platform,\u201d said Peter Gassner, founder and CEO of ³Ô¹Ï±¬ÁÏ. \u201cWe intend to help move the industry forward with a scalable digital trials platform that significantly improves the clinical trial process for patients, sites, and sponsors.\u201d<\/p>\n<p class=\"mb-10\"><strong>Additional Information<\/strong><br \/>\nConnect with ³Ô¹Ï±¬ÁÏ on LinkedIn: <a href=\"https:\/\/www.linkedin.com\/company\/veeva-systems\" target=\"_blank\" rel=\"noopener noreferrer\">linkedin.com\/company\/veeva-systems<\/a><br \/>\nFollow @veevasystems on Twitter: <a href=\"https:\/\/twitter.com\/veevasystems\" target=\"_blank\" rel=\"noopener noreferrer\">twitter.com\/veevasystems<\/a><br \/>\nConnect with LEO Pharma on LinkedIn: <a href=\"https:\/\/www.linkedin.com\/company\/leo-pharma\" target=\"_blank\" rel=\"noopener noreferrer\">linkedin.com\/company\/leo-pharma<\/a><\/p>\n<p class=\"mb-10\"><strong>About ³Ô¹Ï±¬ÁÏ Systems<\/strong><br \/>\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href=\"\/eu\/\">veeva.com\/eu<\/a>.<\/p>\n<p class=\"mb-10\"><strong>About LEO Pharma<\/strong><br \/>\nLEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&#038;D pipeline, a wide range of therapies, and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of EUR 1,359 million. For more information please, visit <a href=\"https:\/\/www.leo-pharma.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">www.LEO-Pharma.com<\/a>.<\/p>\n<p class=\"mb-10\"><strong>Forward-looking Statements<\/strong><br \/>\nThis release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ\u2019s products and services, the results from use of ³Ô¹Ï±¬ÁÏ\u2019s products and services, and general business conditions, particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2021. This is available on the company\u2019s website at <a href=\"\/\" target=\"_blank\" rel=\"noopener noreferrer\">veeva.com<\/a> under the Investors section and on the SEC\u2019s website at <a href=\"https:\/\/sec.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time. <\/p>\n<p class=\"text-center\">###<\/p>\n<p class=\"mb-10\"><strong>Contact:<\/strong><br \/>\nDeivis Mercado<br \/>\n³Ô¹Ï±¬ÁÏ Systems<br \/>\n925-226-8821<br \/>\n<a href=\"mailto:deivis.mercado@veeva.com\">deivis.mercado@veeva.com<\/a><\/p>\n<p><p>Henrik Heskjaer<br \/>\nLEO Pharma<br \/>\n+45 3140 6180<br \/>\n<a href=\"mailto:hdtdk@leo-pharma.com\">hdtdk@leo-pharma.com <\/a><\/p>\n<p>\n","protected":false},"excerpt":{"rendered":"<p>Connected solution aims to deliver faster trials and a better patient experience.<\/p>\n","protected":false},"featured_media":63287,"parent":0,"template":"","class_list":["post-63284","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-data-management","resource-area-20-clinical-operations","resource-area-20-vault-platform-area","resource-product-20-ctms","resource-product-20-dqs","resource-product-20-edc","resource-product-20-etmf","resource-product-20-payments","resource-product-20-sponsor-site-collaboration","resource-product-20-study-startup","resource-product-20-vault-platform","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/63284"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":0,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/63284\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/63287"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=63284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}